NCT00920192 - Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 12, 2009

Primary Completion Date

March 7, 2012

Study Completion Date

March 24, 2015

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Foretinib

Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,

Trial Locations (7)

GSK Investigational Site, Taipei

GSK Investigational Site, Taipei

GSK Investigational Site, Bangkok

GSK Investigational Site, Bangkok

GSK Investigational Site, Khon Kaen

GSK Investigational Site, Tainan City

GSK Investigational Site, Hong Kong